Today, we reported preliminary unaudited financial results and operational updates for the quarter and full year ended December 31, 2022. #oncology #TumorTreatingFields #patientforward https://www.novocure.com/novocure-announces-preliminary-full-year-and-fourth-quarter-2022-net-revenues-and-provides-company-update/
The LUNAR study – evaluating Tumor Treating Fields together with standard therapies – is the first study in more than 6 years to show meaningful improvement in overall survival in stage 4 second-line non-small cell lung cancer. #lungcancer https://www.novocure.com/novocure-announces-pivotal-lunar-study-in-non-small-cell-lung-cancer-met-primary-overall-survival-endpoint/
The LUNAR study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in overall survival over standard therapies alone. https://www.novocure.com/novocure-announces-pivotal-lunar-study-in-non-small-cell-lung-cancer-met-primary-overall-survival-endpoint/
We are participating in the 41st Annual @JPMorgan Healthcare Conference. William Doyle, Novocure’s Executive Chairman, will speak and address questions from analysts on January 10 at 7:30 a.m. PST. https://www.novocure.com/novocure-to-participate-in-41st-annual-j-p-morgan-healthcare-conference/ $NVCR
This #LCAM2022, we are focused on building a united community of #lungcancer patients, caregivers, industry collaborators and advocacy partners to improve access to care and resources. Hear more from our conversation with @GO2ForLungCancr on our commitment to patient education.
Mike Ambrogi, Senior Technology Fellow, will participate in an expert panel 9 a.m. EST Thursday at the @ovariancancerco 2022 Virtual Global Partner Meeting. Panelists will discuss cancer research, innovations and the potential for technology like #TTFields.
Dr. Jesme Fox, Medical Director of @Roy_Castle_Lung, talks about the importance of #lungcancer screenings. Dr. Fox encourages everyone to be proactive and reach out to the lung cancer community for support in navigating a diagnosis and finding helpful resources. #LCAM2022
Today we announced that Health Canada has approved Optune® for the treatment of newly diagnosed and recurrent glioblastoma (GBM). It is the first treatment for GBM approved in Canada in over 12 years. https://www.novocure.com/novocures-optune-approved-in-canada-for-the-treatment-of-newly-diagnosed-and-recurrent-glioblastoma/ #patientforward #canada #btsm #medtech
Innovation and discovery in the lung cancer space is happening fast. Get connected with the #lungcancer advocacy community through organizations like @GO2ForLungCancr to stay up to date on the latest information and resources relevant to your diagnosis.
William Doyle and Ashley Cordova will participate in the 34th Annual Piper Sandler Healthcare Conference on Dec. 1. They will take part in a fireside chat at 9:30 a.m. EST and one-on-one meetings with investors throughout the event. https://www.novocure.com/novocure-to-participate-in-34th-annual-piper-sandler-healthcare-conference/